Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Angela Saviano
 + 1420 word(s) 1420 2021-11-25 06:59:49 |
2 Done
Jason Zhu
Meta information modification 1420 2022-01-10 02:30:36 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Saviano, A. Bacteriocins and Bacteriophages. Encyclopedia. Available online: https://encyclopedia.pub/entry/17879 (accessed on 18 July 2024).
Saviano A. Bacteriocins and Bacteriophages. Encyclopedia. Available at: https://encyclopedia.pub/entry/17879. Accessed July 18, 2024.
Saviano, Angela. "Bacteriocins and Bacteriophages" Encyclopedia, https://encyclopedia.pub/entry/17879 (accessed July 18, 2024).
Saviano, A. (2022, January 07). Bacteriocins and Bacteriophages. In Encyclopedia. https://encyclopedia.pub/entry/17879
Saviano, Angela. "Bacteriocins and Bacteriophages." Encyclopedia. Web. 07 January, 2022.
Bacteriocins and Bacteriophages
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms20010183

Bacteriocins are bactericidal peptides, ribosomally synthesized, with an inhibitory activity against diverse groups of undesirable microorganisms. Bacteriophages are viruses that are able to infect bacterial cells and force them to produce viral components, using a lytic or lysogenic cycle. They constitute a large community in the human gut called the phageome, the most abundant part of the gut virome. 

Bacteriophages Bacteriocins Bacterial Gut

1. Relationship of Bacteriophages and Bacteriocins with the Gut Barrier

In the gut mucosa, bacteriophages select specific bacteria by using horizontal gene transfer, influencing their rate of mutation and genetic variability, and thus modulating their abundance and diversity [1][2]. On the capsid they express Ig (Immunoglobulin)-like receptors, which interact with mucin glycoproteins and can regulate innate and acquired immunity [3]. Thus, bacteriophages can influence bacterial composition, modify their function and interaction with epithelial cells, and modulate the glycoproteic mucin layer and control other microorganism populations both directly and indirectly [4]. Moreover, they are dynamic entities that can translocate across the gut barrier and migrate into the peripheral blood and the peripheral tissue, activating the immune system [4]. They also have a complementary action on dendritic cells and can be considered both activators of inflammation and at the same time anti-inflammatory players [5]. The bacteriophages’ translocation across the gut barrier has been confirmed by different metagenomics studies that revealed their presence in ascitic, urine and blood samples [5][6]. In this scenario, their actions should not only be considered to be focused on the gastrointestinal tract, but also extended to other sites.
Further, bacteriocins act both on the immune system and on the inhibition of competitive strains by directly influencing the niche competition among commensals [7]. Bacteriocins are commonly used strategically by commensals to colonize and persist in the human gut. Their activities could resemble those of a “probiotic”. Indeed, they allow the survival of specific communities in the gastrointestinal tract by selecting strains that are able to resist modification by the host diet, the inhibition of natural defensins, bile salts and other killing factors, and colonization by other species, overall improving gut barrier function and the host immune response [8]. Studies on animal ilea have confirmed the potential effects of bacteriocin against pathogens, which led to positive changes in the gut microbiota composition. This is the case of Bacteriocin Abp118 [9], produced by Lactobacillus salivarius UCC118 [10] or salivaricin P, produced by another Lactobacillus salivarius strain with a probiotic trait [9]. Interestingly, Lactobacillus salivarius expresses the srtA gene to tie it to the epithelial cell’s surface, before producing protective bacteriocins [9]. Bactofencin A or bacteriocin 21 produced by Enterococcus faecalis are able to kill multidrug resistant-bacteria and contribute to the regulation of the niche competition among intestinal bacteria [7]. Similarly, LAB bacteriocins exert their role against Staphylococcus Aureus [11], some vancomycin-resistant enterococci [7], Salmonella enteritidis [11], Clostridium Difficile [12] and Listeria monocytogenes [11]. More studies are needed to test the therapeutic potential of these findings. At the same time, it should be noted that not all changes observed in vitro have also been registered in vivo. This discrepancy is not surprising since several perturbing factors can deeply affect bacteriocin production and their activities.

2. Bacteriophages and Bacteriocins in Bacterial Food Infections

The antibacterial properties of bacteriophages and bacteriocins are exploited in food research. In particular, bacteriocins are used as food preservatives [13] both for dairy products [14] and for meat, fish [15], vegetables and fruits [16], being classified as partially purified bacteriocins, crude-fermented dairy bacteriocins and protective cultures bacteriocins [17].
Bacteriocins are considered natural and safe food additives after being ingested by the gastrointestinal tract [18]. They have the interesting properties of stability, antimicrobial effects, potency, and no flavor alteration [18].
There are different commercially available bacteriocins such as nisin (named Nisaplin) or Pediocin PA-1 against the growth of Listeria monocytogenes in meat products [19]. Other bacteriocins, such as those produced by Enterococci, seem to reduce the contamination of cheese due to animal feces [20], while Enterocin AS-48, Enterocin CCM4231 and EJ97 are used to protect both fermented and unfermented vegetables [19]. Bacteriocins can be added to food through the direct inoculation of the producer-strains as a concentrated fermented product [19] or as a gradual-release preparation. They have antimicrobial activity against gram-negative bacteria that infect foods, and this property could be empowered by combining bacteriocins with other compounds (e.g., organic acids, phenolic compounds). Other antimicrobial bacteriocins involved in food protection belong to the class I and II bacteriocins of Bacillus subtilis GAS101 and act against some gram-positive bacterial species such as Staphylococcus Epidermidis [21]. Bacteriocins are overall able to reduce the costs of food treatments and at the same time increase the product shelf-life.
Similarly, bacteriophages are used against Salmonella, Campylobacter and Enterococcus on food [22]. The efficacy of bacteriophages is reduced by their spectrum of action, which is oriented against specific serotypes, species or strains of bacteria [22]. However, their narrow spectrum could be more advantageous than antibiotics and may have a lower impact on the other components of the gut microbiota [23].
Bacteriophages can also control the production of some pathogenic toxins such as Cholera, Shiga and Pertussis, and interfere with mechanisms of antibiotic resistance [24]. In the past, they have been used to control the epidemic of bloody diarrhea in Germany caused by E. coli strain 0104:H4 through the production of Shiga toxins [25].
Finally, an alteration of gut virome composition could also be found in recurrent Clostridium Difficile infection [26]. Interestingly, the presence of a complex of bacteriophages in fecal mass used for therapeutic fecal microbiota transplantation (FMT) has been demonstrated to improve clinical outcomes of this treatment [27].

3. Role of Bacteriophages and Bacteriocins in Extra-Intestinal Diseases

Bacteriophage therapy has strong potential as a treatment for many extra-intestinal diseases, and in particular in those correlated to bacterial infections [28]. Indeed, in chronic bacterial rhino-sinusitis, after twenty days of topical application, a bacteriophage cocktail (P68, K710) is able to control a broad range of Staphylococcus Aureus (S. aureus) strains, including the methicillin-resistant strain (MRSA) [28]. A common manifestation of invasive S. aureus infection is osteomyelitis. S. aureus triggers many profound alterations in bone remodeling. Bacteriophage therapy has been applied with promising results, but more data are needed to confirm these findings [29].
In animal models, it has been reported that bacteriophages are able to control Pseudomonas lung infections [12]. In fact, two bacteriophages, φMR299-2 and φNH-4, have been proven to induce the formation of a biofilm on lung cells useful in controlling these infections. Hypothetically, they could have beneficial effects in patients with cystic fibrosis who are mostly exposed to this microorganism [30].
Bacteriophage therapy has been also used successfully for acne treatment. Acne has a multifactorial etiology and the inflammatory follicular response caused by the gram-positive skin bacterium Propionibacterium Acnes seems to play a primary role. The most common first line treatment is based on topical antimicrobial agents or oral antibiotics. Recent data suggest an alternative treatment, both for acne and for others bacterial skin infections, based on the use of a lytic bacteriophage preparation able to kill specific bacterial cells [31].
Further advantages of bacteriophage treatment have been demonstrated for diabetic foot ulcer healing. A commercial topical preparation of staphylococcal bacteriophage Sb-1 is effective when antibiotic treatment is unsuccessful [32].
On the contrary, bacteriocins such as pyocin were unable to control Pseudomonas lung infections in patients with cystic fibrosis. In fact, despite initial positive laboratory experiments, subsequent studies have underlined no evidence of beneficial effects for this bacteriocin [33].
Another frequent infection is provoked by Streptococcus Pneumoniae, which is responsible for pneumonia, bacteremia and meningitis, in particular in children. Pneumococcal disease benefit from vaccine and antibiotic treatment, but resistance is increasing. S. Pneumoniae is common in the nasopharynx of children, and it produces a circular bacteriocin, known as pneumocyclicin, to attack other bacteria and to protect itself against the immune system. This bacteriocin is similar to the other circular bacteriocins produced by gram-positive bacteria, and it could represent an important target thanks to its correlation to antibiotic resistance mechanisms [34].
Overall, bacteriophage therapy could be very beneficial thanks to its action against all types of pathogens, including those that are multi-drug resistant. A positive aspect of their narrow spectrum is the possibility of preserving the existing microbiome. Bacteriophages also have lower side effects, a wide distribution after their administration, and a possible inhibitory effect on the inflammatory response. They are cost effective and some studies underline their efficacy in comparison with antibiotics [23]. Further, bacteriocins could be very useful in fighting pathogens. They are easier to modify through bioengineering and have targeted activity against specific microorganisms. Numerous studies are trying to prove their use as a natural defense and as an alternative to antibiotics [13] in peculiar cases such as pregnant women and in individuals with contraindications to antibiotic use [35].

References

  1. Wang, J.; Hu, B.; Xu, M.; Yan, Q.; Liu, S.; Zhu, X.; Sun, Z.; Reed, E.; Ding, L.; Gong, J.; et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 2006, 17, 309–317.
  2. Matsuzaki, S.; Yasuda, M.; Nishikawa, H.; Kuroda, M.; Ujihara, T.; Shuin, T.; Shen, Y.; Jin, Z.; Fujimoto, S.; Nasimuzzaman, M.D.; et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J. Infect. Dis. 2003, 187, 613–624.
  3. Barr, J.J.; Auro, R.; Furlan, M.; Whiteson, K.L.; Erb, M.L.; Pogliano, J.; Stotland, A.; Wolkowicz, R.; Cutting, A.S.; Doran, K.S.; et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl. Acad. Sci. USA 2013, 110, 10771–10776.
  4. Lusiak-Szelachowska, M.; Weber-Dabrowska, B.; Jonczyk-Matysiak, E.; Wojciechowska, R.; Gorski, A. Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog. 2017, 9, 44.
  5. Brown-Jaque, M.; Muniesa, M.; Navarro, F. Bacteriophages in clinical samples can interfere with microbiological diagnostic tools. Sci. Rep. 2016, 6, 33000.
  6. Thannesberger, J.; Hellinger, H.J.; Klymiuk, I.; Kastner, M.T.; Rieder, F.J.J.; Schneider, M.; Fister, S.; Lion, T.; Kosulin, K.; Laengle, J.; et al. Viruses comprise an extensive pool of mobile genetic elements in eukaryote cell cultures and human clinical samples. FASEB J. 2017, 31, 1987–2000.
  7. Kommineni, S.; Bretl, D.J.; Lam, V.; Chakraborty, R.; Hayward, M.; Simpson, P.; Cao, Y.; Bousounis, P.; Kristich, C.J.; Salzman, N.H. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature 2015, 526, 719–722.
  8. O’Toole, P.W.; Cooney, J.C. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip. Perspect. Infect. Dis. 2008, 2008, 175285.
  9. Hegarty, J.W.; Guinane, C.M.; Ross, R.P.; Hill, C.; Cotter, P.D. Bacteriocin production: A relatively unharnessed probiotic trait? F1000Res 2016, 5, 2587.
  10. Umu, O.C.; Bauerl, C.; Oostindjer, M.; Pope, P.B.; Hernandez, P.E.; Perez-Martinez, G.; Diep, D.B. The Potential of Class II Bacteriocins to Modify Gut Microbiota to Improve Host Health. PLoS ONE 2016, 11, e0164036.
  11. Umu, O.C.O.; Rudi, K.; Diep, D.B. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health Dis. 2017, 28, 1348886.
  12. Rea, M.C.; Alemayehu, D.; Ross, R.P.; Hill, C. Gut solutions to a gut problem: Bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J. Med. Microbiol. 2013, 62 Pt 9, 1369–1378.
  13. Oldak, A.; Zielinska, D. Bacteriocins from lactic acid bacteria as an alternative to antibiotics. Postepy Hig. Med. Dosw. (Online) 2017, 71, 328–338.
  14. Linares, D.M.; Gomez, C.; Renes, E.; Fresno, J.M.; Tornadijo, M.E.; Ross, R.P.; Stanton, C. Lactic Acid Bacteria and Bifidobacteria with Potential to Design Natural Biofunctional Health-Promoting Dairy Foods. Front. Microbiol. 2017, 8, 846.
  15. Francoise, L. Occurrence and role of lactic acid bacteria in seafood products. Food Microbiol. 2010, 27, 698–709.
  16. Di Cagno, R.; Coda, R.; De Angelis, M.; Gobbetti, M. Exploitation of vegetables and fruits through lactic acid fermentation. Food Microbiol. 2013, 33, 1–10.
  17. Chikindas, M.L.; Weeks, R.; Drider, D.; Chistyakov, V.A.; Dicks, L.M. Functions and emerging applications of bacteriocins. Curr. Opin. Biotechnol. 2017, 49, 23–28.
  18. Yang, S.C.; Lin, C.H.; Sung, C.T.; Fang, J.Y. Antibacterial activities of bacteriocins: Application in foods and pharmaceuticals. Front. Microbiol. 2014, 5, 241.
  19. Settanni, L.; Corsetti, A. Application of bacteriocins in vegetable food biopreservation. Int. J. Food Microbiol. 2008, 121, 123–138.
  20. Foulquie Moreno, M.R.; Sarantinopoulos, P.; Tsakalidou, E.; De Vuyst, L. The role and application of enterococci in food and health. Int. J. Food Microbiol. 2006, 106, 1–24.
  21. Sharma, G.; Dang, S.; Gupta, S.; Gabrani, R. Antibacterial Activity, Cytotoxicity, and the Mechanism of Action of Bacteriocin from Bacillus subtilis GAS101. Med. Princ. Pract. 2018, 27, 186–192.
  22. Wernicki, A.; Nowaczek, A.; Urban-Chmiel, R. Bacteriophage therapy to combat bacterial infections in poultry. Virol. J. 2017, 14, 179.
  23. Wittebole, X.; De Roock, S.; Opal, S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014, 5, 226–235.
  24. Norman, J.M.; Handley, S.A.; Baldridge, M.T.; Droit, L.; Liu, C.Y.; Keller, B.C.; Kambal, A.; Monaco, C.L.; Zhao, G.; Fleshner, P.; et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015, 160, 447–460.
  25. Merabishvili, M.; De Vos, D.; Verbeken, G.; Kropinski, A.M.; Vandenheuvel, D.; Lavigne, R.; Wattiau, P.; Mast, J.; Ragimbeau, C.; Mossong, J.; et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS ONE 2012, 7, e52709.
  26. Broecker, F.; Russo, G.; Klumpp, J.; Moelling, K. Stable core virome despite variable microbiome after fecal transfer. Gut Microbes 2017, 8, 214–220.
  27. Ott, S.J.; Waetzig, G.H.; Rehman, A.; Moltzau-Anderson, J.; Bharti, R.; Grasis, J.A.; Cassidy, L.; Tholey, A.; Fickenscher, H.; Seegert, D.; et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017, 152, 799e7–811e7.
  28. Drilling, A.J.; Ooi, M.L.; Miljkovic, D.; James, C.; Speck, P.; Vreugde, S.; Clark, J.; Wormald, P.J. Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region. Front. Cell. Infect. Microbiol. 2017, 7, 49.
  29. Abedon, S.T. Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model. Front. Microbiol. 2016, 7, 1251.
  30. Alemayehu, D.; Casey, P.G.; McAuliffe, O.; Guinane, C.M.; Martin, J.G.; Shanahan, F.; Coffey, A.; Ross, R.P.; Hill, C. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012, 3, e00029-12.
  31. Brown, T.L.; Petrovski, S.; Dyson, Z.A.; Seviour, R.; Tucci, J. The Formulation of Bacteriophage in a Semi Solid Preparation for Control of Propionibacterium acnes Growth. PLoS ONE 2016, 11, e0151184.
  32. Fish, R.; Kutter, E.; Wheat, G.; Blasdel, B.; Kutateladze, M.; Kuhl, S. Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials. Methods Mol. Biol. 2018, 1693, 159–170.
  33. Ghoul, M.; West, S.A.; Johansen, H.K.; Molin, S.; Harrison, O.B.; Maiden, M.C.; Jelsbak, L.; Bruce, J.B.; Griffin, A.S. Bacteriocin-mediated competition in cystic fibrosis lung infections. Proc. Biol. Sci. 2015, 282.
  34. Bogaardt, C.; van Tonder, A.J.; Brueggemann, A.B. Genomic analyses of pneumococci reveal a wide diversity of bacteriocins—Including pneumocyclicin, a novel circular bacteriocin. BMC Genom. 2015, 16, 554.
  35. Hammami, R.; Fernandez, B.; Lacroix, C.; Fliss, I. Anti-infective properties of bacteriocins: An update. Cell. Mol. Life Sci. 2013, 70, 2947–2967.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Angela Saviano
View Times: 468
Entry Collection: Peptides for Health Benefits
Revisions: 2 times (View History)
Update Date: 10 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback